Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05040880
Other study ID # IN_TMP_101
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date July 8, 2021
Est. completion date October 31, 2021

Study information

Verified date February 2022
Source HK inno.N Corporation
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To compare the pharmacokinetics and safety after a single dose administration of Telmione plus® 80/12.5mg and Micardis plus® 80/12.5mg in healthy adult volunteers


Recruitment information / eligibility

Status Completed
Enrollment 46
Est. completion date October 31, 2021
Est. primary completion date October 31, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 19 Years and older
Eligibility Inclusion Criteria: - Healthy adult volunteers aged = 19 years at screening - Body weight = 50kg and Body mass index (BMI) in the range of 18.0 and 30.0 kg/? - Subjects who do not have congenital or chronic diseases requiring treatment and have no pathological symptoms or findings as a result of physical examination - Determined by the investigator to be eligible for study participation based on the results of screening tests (clinical laboratory tests, vital signs, physical examination, 12-lead ECG) conducted according to the IP characteristics - Subjects who decided to participate in the study and signed informed consent form voluntarily after receiving detailed explanation of the study and fully understanding Exclusion Criteria: - Subjects with a presence and a history of clinically significant hepatic, renal, neurology, psychiatric, pulmonary, endocrine, hematologic, oncologic, genitourinary, cardiovascular, gastrointestinal, musculoskeletal disease - Pregnant(positive urine HCG) or breastfeeding women if female - Subjects with a hereditary problems, for example, galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption - Subjects with a presence and a history of surgery or gastrointestinal diseases which might significantly change absorption of medicines - Subjects with hypersensitivity or a history of clinically significant hyper sensitivity to ingredients with IPs, excipients, other drugs including sulfonamide and renin-angiotensin class - Subjects with the following results in clinical laboratory tests - AST/ALT/ALP/?-GTP/Bilirubin total > UNL (upper normal limit) × 2 - Creatinine in plasma which is outside the accepted normal range or eGFR calculated by MDRD < 60 mL/min/1.73 ? - CK > UNL × 2 - Subjects with a history of drug abuse or positive to drug abuse at urine drug screening test - Subjects with systolic blood pressure (SBP) = 140 mmHg or = 90 mmHg, diastolic blood pressure (DBP) = 100 mmHg or = 60 mmHg, or pulse rate (PR) = 40 bpm or = 100 bpm on vital signs measured in sitting position after taking a rest for at least 3 minutes during screening test - Subjects with clinically significant opinions including the following results in 12-lead ECG test during screening test - QTc > 450 ms - PR interval > 200 ms - QRS duration > 120 ms - Subjects who have an abnormal diet that can affect ADME of drugs or consume foods that can affect drug metabolism - Subjects who have taken any prescription drugs or herbal medicine within 2 weeks prior to the 1st IP administration, or any over-the-counter (OTC) drug, health functional food or vitamin preparation within 10 days to the 1st IP administration (However, can participate in the study if otherwise eligible in the judgment of the investigator) - Subjects who have taken the drug which can induce or inhibit drug metabolism enzyme within 1 month prior to the 1st IP administration - Subjects who have participated in any other clinical study or bioequivalnece study within 6 months prior to the 1st IP administration(However, the criterion for termination of participation in other clinical study or bioequivalence study is the last administration date, and the next day is counted as one day.) - Subjects who have donated whole blood within 2 months prior to the 1st IP administration or have donated blood components or received transfusion within 1 month prior to the 1st IP administration - Subject who have continued drink of alcohol (> 21 units/week, 1 unit = 10 g = 12.5 mL of pure alcohol) within 6 months prior to the 1st IP administration or are unable to stop drinking from the time of signing the informed consent form to post study visit - alcohol (g) = intake volume(mL) × level(%) × 0.8 - Subject who have a history of excessive smoking (> 10 cigarettes/day) within 3 months prior to the 1st IP administration and unable to stop smoking from 24 hours before the administration at each period to the last sampling time at each period - Subjects who take or are unable to stop foods containing grapefruit from 48 hours before the 1st IP administration to post study visit - Subject who take or are unable to stop foods containing caffeine(coffee, green tea, black tee, soda, coffee-flavored milk, nutritive tonic drink) from 24 hours before the administration at each period to the last sampling time at each period - Subjects who have exercised vigorously exceeding the level of daily life during the period from 48 hours before the 1st administration to post study visit, or who are unable to stop vigorous exercise - Subjects or their spouse or partner who are not using an approved method of contraception or even if are not planning to become pregnant (e.g., contraceptive administration and implantation, intrauterine device, Those who are not using procedures (vasectomy, tubal ligation, etc.) from the time of written consent of the subject until two weeks after the last bioequivalence study drug administration date - Subjects who have determined that the investigator is unsuitable to participate in the bioequivalence test due to reasons other than the above selection/exclusion criteria

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Telmione plus 80/12.5mg
Test drug (Fixed-dose combination drug of telmisartan 80mg and hydrochlorothiazide 12.5mg)
Micardis plus 80/12.5mg
Reference drug (Fixed-dose combination drug of telmisartan 80mg and hydrochlorothiazide 12.5mg)

Locations

Country Name City State
Korea, Republic of Chungbuk National University Hospital Cheongju-si Chungcheongbuk-do

Sponsors (1)

Lead Sponsor Collaborator
HK inno.N Corporation

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary Cmax of telmisartan Up to 72 hours
Primary AUClast of telmisartan Up to 72 hours
Primary Cmax of hydrochlorothiazide Up to 72 hours
Primary AUClast of hydrochlorothiazide Up to 72 hours
Secondary Tmax of telmisartan Up to 72 hours
Secondary AUCinf of telmisartan Up to 72 hours
Secondary t1/2 of telmisartan Up to 72 hours
Secondary CL/F of telmisartan Up to 72 hours
Secondary Vd/F of telmisartan Up to 72 hours
Secondary Tmax of hydrochlorothiazide Up to 72 hours
Secondary AUCinf of hydrochlorothiazide Up to 72 hours
Secondary t1/2 of hydrochlorothiazide Up to 72 hours
Secondary CL/F of hydrochlorothiazide Up to 72 hours
Secondary Vd/F of hydrochlorothiazide Up to 72 hours
See also
  Status Clinical Trial Phase
Terminated NCT04591808 - Efficacy and Safety of Atorvastatin + Perindopril Fixed-Dose Combination S05167 in Adult Patients With Arterial Hypertension and Dyslipidemia Phase 3
Recruiting NCT04515303 - Digital Intervention Participation in DASH
Completed NCT05433233 - Effects of Lifestyle Walking on Blood Pressure in Older Adults With Hypertension N/A
Completed NCT05491642 - A Study in Male and Female Participants (After Menopause) With Mild to Moderate High Blood Pressure to Learn How Safe the Study Treatment BAY3283142 is, How it Affects the Body and How it Moves Into, Through and Out of the Body After Taking Single and Multiple Doses Phase 1
Completed NCT03093532 - A Hypertension Emergency Department Intervention Aimed at Decreasing Disparities N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Recruiting NCT05529147 - The Effects of Medication Induced Blood Pressure Reduction on Cerebral Hemodynamics in Hypertensive Frail Elderly
Recruiting NCT05976230 - Special Drug Use Surveillance of Entresto Tablets (Hypertension)
Completed NCT06008015 - A Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1015" and Co-administration of "BR1015-1" and "BR1015-2" Under Fed Conditions in Healthy Volunteers Phase 1
Completed NCT05387174 - Nursing Intervention in Two Risk Factors of the Metabolic Syndrome and Quality of Life in the Climacteric Period N/A
Completed NCT04082585 - Total Health Improvement Program Research Project
Recruiting NCT05121337 - Groceries for Black Residents of Boston to Stop Hypertension Among Adults Without Treated Hypertension N/A
Withdrawn NCT04922424 - Mechanisms and Interventions to Address Cardiovascular Risk of Gender-affirming Hormone Therapy in Trans Men Phase 1
Active, not recruiting NCT05062161 - Sleep Duration and Blood Pressure During Sleep N/A
Completed NCT05087290 - LOnger-term Effects of COVID-19 INfection on Blood Vessels And Blood pRessure (LOCHINVAR)
Not yet recruiting NCT05038774 - Educational Intervention for Hypertension Management N/A
Completed NCT05621694 - Exploring Oxytocin Response to Meditative Movement N/A
Completed NCT05688917 - Green Coffee Effect on Metabolic Syndrome N/A
Recruiting NCT05575453 - OPTIMA-BP: Empowering PaTients in MAnaging Blood Pressure N/A
Completed NCT04303468 - Intervention With a GABA Supplement in Prediabetics N/A